ClinicalTrials.gg
Status unknownNCT05215925Updated Jul 6, 2022

A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression

A Phase 2 interventional study of HLX07+carboplatin+pemetrexed and HLX07+docetaxel in HLX07, nsqNSCLC, High EGFR Expression, sponsored by Shanghai Henlius Biotech. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-06.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

An Open-label, Multicenter , Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Combination with Chemotherapy or Monotherapy in Advanced Non-squamous Non-small Cell Lung Cancer (nsqNSCLC) Patients with High EGFR Expression

02

Conditions studied

  • HLX07, nsqNSCLC, High EGFR Expression
03

In context

Lead sponsor

Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age>=18Y
  2. Good Organ Function
  3. Expected survival time ≥ 3 months
  4. confirmed, advanced/recurrent or nsqNSCLC
  5. according RECISTv1.1 by investigator
  6. High EGFR expression H score ≥200
  7. score 0-1

Exclusion criteria

Exclusion Criteria:

  1. Histologically, squamous NSCLC should be excluded. For tumors with adenocarcinoma and squamous carcinoma, if the adenoid component is dominant and the squamous component is \< 5%, the patients meet the inclusion requirements.
  2. Previous treatment with EGFR inhibitors
  3. Symptomatic brain or meningeal (unless the patient has been on > treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable).
  4. Active clinical severe infection;
  5. A history of other within 5 years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin,etal.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    A

    Drug: HLX07+carboplatin+pemetrexed

  • Experimental
    B

    Drug: HLX07+docetaxel

  • Experimental
    C

    Drug: HLX07

Interventions

  • DrugHLX07+carboplatin+pemetrexed

    Drug pages: HLX07 · Carboplatin · Pemetrexed

    HLX07 1500mg q3w+carboplatin+pemetrexed

    Also known as: Anti-EGFR Monoclonal Antibody

  • DrugHLX07+docetaxel

    Drug pages: HLX07 · Docetaxel

    HLX07 1500mg q3w+docetaxel

  • DrugHLX07

    HLX07 1500mg q3w

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate(assessed by independent radiological review committee (IRRC) based on the RECIST Version 1.1)

    Time frame: up to 2 years

  2. PFS

    Progression-free survival (PFS) (assessed by IRRC and the investigator as per RECIST v1.1

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years

Secondary outcomes

  1. OS

    Overall survival

    Time frame: from the date of first dose until the date of death from any cause,assessed up to 2 years

07

Study locations

1 site
  • Shanghai Chest Hospital
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2023; primary completion for Jul 2023, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2022
First posted
Jan 31, 2022
StartEst.
Feb 1, 2023
Primary completionEst.
Jul 15, 2023
CompletionEst.
Aug 10, 2024
Last update
Jul 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05215925
Responsible party
Sponsor
First posted
Jan 31, 2022
Start date
Feb 1, 2023 (estimated)
Primary completion
Jul 15, 2023 (estimated)
Completion
Aug 10, 2024 (estimated)
Last update
Jul 6, 2022

Study contacts

baohui han, phD
Contact
hanxkyy@aliyun.com
021-22200000

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HLX07 · Carboplatin · Pemetrexed · Docetaxel

Start the discussion